[Effect of thymalin on the status of immunogenesis and hemostasis in patients with ischemic heart disease].
Kuznik. B I BI; Budazhabon. G B GB; Sytnikova. I A IA; Morozov. V G VG; Khavinson. V Kh VKh
Key Findings
- Cellular and humoral immunity returned to normal
- Blood coagulation slowed with lower fibrinogen and FDP
- Total euglobulin and Hageman‑dependent fibrinolysis increased
- Angina pain resolved more quickly
Practical Outcomes
- Thymalin shows some promise for supporting immune balance and modest anticoagulant effects, but the data come from a specific heart‑disease group and lack clear dosing or safety details. For biohackers, it’s an experimental option that would need careful self‑monitoring and likely medical supervision before use.
Summary
In a study of heart‑disease patients, adding the peptide thymalin to standard treatment helped bring immune markers back to normal, slowed down blood clotting, lowered fibrinogen and FDP levels, boosted the body’s ability to break down clots, and made chest‑pain episodes disappear faster than in patients who didn’t get the peptide.
Abstract
It was established that the use of thymalin in multimodality therapy of CHD patients suffering from attacks of angina pectoris of effort and at rest brought back to normal the state of cellular and humoral immunity, slowed down blood coagulation, decreased fibrinogen and FDP concentration, enhanced total euglobulin and Hageman-dependent fibrinolysis. A more rapid disappearance of the pain syndrome was noted in these patients as compared to those who had not received the drug.
Study Information
pubmed
1986